Creabilis rounds up $30M

CompanyAmount/RoundLead InvestorsDescription


Creabilis Therapeutics
Italy
$30.6M
First
Sofinnova Partners

The money is earmarked for three mid-stage studies of CT327 for psoriasis and dermatitis and CT200, which is being developed for Behcet's Disease.

IRX Therapeutics
New York
$25M
First
Existing investors

The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment.

Inimex Pharmaceuticals
Canada
$22M
Second
Morningside Venture Investments

The company is launching the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and assessing IDR drugs in a range of disease models.

Creabilis rounds up $30M

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.